PART I Overview Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. We have developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. We commercialize our products, consisting of Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR (collectively the Nucynta ...
Q2 FY2026 — expected 2026-08-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001628280-26-011992 | EDGAR | 75K words |
| 2025-02-27 | 2024-12-31 | 0001558370-25-001801 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0001558370-24-001526 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001558370-23-001900 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001558370-22-001927 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001558370-21-001814 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001558370-20-001625 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001558370-19-001187 | EDGAR | — |
| 2018-03-07 | 2017-12-31 | 0001558370-18-001644 | EDGAR | — |
| 2017-03-10 | 2016-12-31 | 0001558370-17-001629 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001104659-25-107391 | EDGAR | 48K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010649 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001558370-25-006960 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014858 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011586 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001558370-24-007601 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001558370-23-017983 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001558370-23-013192 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001558370-23-008087 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001558370-22-016241 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001558370-22-012184 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001558370-22-008090 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-19 | 0001104659-26-032166 | EDGAR | 52K words |
| 2026-02-26 | 0001628280-26-011990 | EDGAR | — |
| 2026-01-08 | 0001104659-26-001953 | EDGAR | — |
| 2025-12-30 | 0001104659-25-125026 | EDGAR | — |
| 2025-11-06 | 0001104659-25-107389 | EDGAR | — |
| 2025-08-07 | 0001558370-25-010647 | EDGAR | — |
| 2025-07-07 | 0001104659-25-065981 | EDGAR | — |
| 2025-05-19 | 0001104659-25-050435 | EDGAR | — |
| 2025-05-12 | 0001104659-25-047040 | EDGAR | — |
| 2025-05-08 | 0001558370-25-006957 | EDGAR | — |
185 total filings indexed. 153 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001267565 |
| Ticker | COLL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | VA |
| Website | https://www.collegiumpharma.com |
| Listed | 2015-05-07 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report